Andere Sprachen Inhibrx, Inc.

Aktien

A2PQMH

US45720L1070

INBX

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:17:18 23.05.2024			% 5 Tage	% 1. Jan.
34,32 ^USD	-0,26 %		-0,39 %	-9,59 %

09.05.	Inhibrx, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
28.02.	Inhibrx-Aktien fallen nach Ausweitung des Q4-Nettoverlustes	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off	11.05.
Inhibrx : Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Form 8-K	09.05.
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX	09.05.
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger	08.05.
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX	27.03.
Inhibrx Shares Fall After Q4 Net Loss Widens	28.02.
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M	28.02.
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results	28.02.
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX	10.02.
Le bric-à-brac de Zonebourse : Trois records historiques, une galaxie lointaine et du M&A	06.02.
Arecor Therapeutics hails Arestat as 2023 performance "strong"	01.02.
Sanofi bets $1.7b on potential best-in-class rare disease therapy	24.01.
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline	24.01.
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results	24.01.
Health Care Flat After J&J Earnings -- Health Care Roundup	23.01.
Arecor pleased as investee Inhibrx sells therapy to Sanofi	23.01.
Sector Update: Health Care Stocks Decline Late Afternoon	23.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Inhibrx, Inc.

Aktien

A2PQMH

US45720L1070

INBX

Andere Sprachen

Filter